Mandashi is pleased to announce its first investment in Rarecan. Rarecan believes people with rare cancer have the right to live better, longer lives. They make this happen by bringing people together to create opportunities to accelerate research.
Rarecan is developing a modern digital platform through which people with rarer forms of cancer will be able to share their data with researchers to speed up the discovery of new diagnostics and treatments.
Dr Evans, Director for Mandashi, said: "We're very pleased to be making our first investment in a business which has the potential to make a huge difference to people's lives".
"We urgently need to increase treatment options and improve outcomes for people with rare cancer. With the investment from Mandashi, RareCan is using technology to help put patients, who are willing to take part in trials, in front of researchers". (Piers Kotting, CEO for Rarecan).
"We were really impressed with the vision and goals of Rarecan, and also with the team who are both extremely experienced in their fields, but also very committed to the success of Rarecan. It is the quality of the people that make the businesses we invest in successful, and that quality shines through within Rarecan".